{
    "nctId": "NCT00172068",
    "briefTitle": "Zoledronic Acid in the Treatment of Breast Cancer With Minimal Residual Disease in the Bone Marrow",
    "officialTitle": "Efficacy and Tolerability of Intravenous Zometa\u00ae (Zoledronic Acid) 4 mg in Primary Breast Cancer Patients With Disseminated Tumor Cells in Bone Marrow. A Prospective, Randomized, Parallel Group, Open-label, Clinical Pilot Study.",
    "overallStatus": "TERMINATED",
    "conditions": "Primary Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 96,
    "primaryOutcomeMeasure": "Reduction of detected tumor cells in bone marrow",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Patients, with primary breast cancer who had undergone complete primary tumor resection and axillary lymph node dissection\n* Evidence of minimal residual disease (disseminated tumor cells in bone marrow)\n* Patients had to receive one of the following adjuvant therapy categories: chemotherapy \u00b1 hormonal therapy or hormonal therapy alone\n\nExclusion Criteria:\n\n* Inflammatory, metastatic or recurrent breast cancer or a history of breast cancer prior to the currently diagnosed case\n* Neo-adjuvant chemotherapy, neo-adjuvant hormonal therapy, or neo-adjuvant radiotherapy\n* Prior stem cell rescue/bone marrow transplant\n* History of other cancers aside from non-melanomatous skin cancer or carcinoma in situ of the uterine cervix\n\nAdditional protocol-defined inclusion / exclusion criteria may apply",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}